Chiron Real Estate Inc.
XRNReal EstateNASDAQREIT - Healthcare Facilities · Last scanned Sep 8, 2026
Scan Results
Daily timeframeChiron is a real estate investment trust focused on investing in the future of healthcare. The company carries a $535.2M market cap, placing it firmly in the small-cap category. At Chiron we strive to deliver value at the intersection of care, capital and real estate.
Market Cap
$535.2M
Beta
1.13
P/E (TTM)
9.94
P/E (Fwd)
-9.01
EPS (TTM)
$3.72
EPS (Fwd)
$-4.10
ROE
10.4%
ROA
1.8%
Cash
$21.6M
Total Debt
$646.5M
Free CF
$95.0M
52W Change
-2.1%
Annual Financials
Cash vs Debt
Where XRN stands vs its 150-day and 200-day moving averages
As of the August 26, 2026 close, XRN finished 7.60% above its 150-day moving average ($35.01) and 9.83% above its 200-day moving average ($34.30). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XRN overbought or oversold?
At the August 26, 2026 close, XRN's RSI(14) was 70.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Chiron Real Estate Inc. carries $646.5M in total debt against $21.6M in cash reserves — debt is roughly 30.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $95.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 10.4%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.8% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $137.2M (2022) to $147.7M (2025).
Chiron Real Estate Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing XRN.